322 results on '"Tokimatsu, Issei"'
Search Results
102. Pathogenesis of Trichosporon asahii and Strategies for Infectious Control of Disseminated Trichosporonosis
- Author
-
Tokimatsu, Issei, primary, Karashima, Reiko, additional, Yamagata, Eiji, additional, Yamakami, Yuriko, additional, Nagai, Hiroyuki, additional, Kadota, Jun-ichi, additional, and Nasu, Masaru, additional
- Published
- 2003
- Full Text
- View/download PDF
103. Clinical Characterization of blaIMP Positive Gram-negative Rods Isolated Cases
- Author
-
NAKANO, Tetsuji, primary, HIRAMATSU, Kazufumi, additional, HIRATA, Norio, additional, MURAKAMI, Junko, additional, ICHIMIYA, Tomoku, additional, TOKIMATSU, Issei, additional, YAMAGATA, Eiji, additional, YAMAKAMI, Yuriko, additional, YAMASAKI, Tohru, additional, NAGAI, Hiroyuki, additional, KADOTA, Jun-ichi, additional, NASU, Masaru, additional, NAKANO, Tadao, additional, and SAIKAWA, Tetsunori, additional
- Published
- 2001
- Full Text
- View/download PDF
104. Recent Knowledge Allowing Diagnosis and Treatment of Deep-Seated Trichosporonosis.
- Author
-
Yamakami, Yuriko, primary, Yamagata, Eiji, additional, Karashima, Reiko, additional, Tokimatsu, Issei, additional, Hashimoto, Atsuro, additional, Nagai, Hiroyuki, additional, Nasu, Masaru, additional, and Kamberi, Perparim, additional
- Published
- 2000
- Full Text
- View/download PDF
105. PCR Detection of DNA Specific for Trichosporon Species in Serum of Patients with Disseminated Trichosporonosis
- Author
-
Nagai, Hiroyuki, primary, Yamakami, Yuriko, additional, Hashimoto, Atsuro, additional, Tokimatsu, Issei, additional, and Nasu, Masaru, additional
- Published
- 1999
- Full Text
- View/download PDF
106. Genetic Determinants Responsible for Acquisition of Dengue Type 2 Virus Mouse Neurovirulence
- Author
-
Bray, Michael, primary, Men, Ruhe, additional, Tokimatsu, Issei, additional, and Lai, Ching-Juh, additional
- Published
- 1998
- Full Text
- View/download PDF
107. Clinical Study on Mechanism ofPneumocystis cariniiPneumonia by Polymerase Chain Reaction
- Author
-
HASHIMOTO, Atsuro, primary, MIZUNOE, Shunji, additional, TOKIMATSU, Issei, additional, NAKAMA, Kaoru, additional, YAMAGATA, Eiji, additional, YAMAKAMI, Yuriko, additional, NAGAI, Hiroyuki, additional, and NASU, Masaru, additional
- Published
- 1998
- Full Text
- View/download PDF
108. A Pathological Study of Cytomegalovirus Infections in Autopsied Cases with Adult T-Cell Leukemia
- Author
-
NAGAOKA, Hiroshi, primary, TOKIMATSU, Issei, additional, YAMASAKI, Tohru, additional, NAGAI, Hiroyuki, additional, OTSUKA, Eiichi, additional, HASHIMOTO, Atsuro, additional, GOTO, Yoichiro, additional, NASU, Masaru, additional, KIKUCHI, Hiroshi, additional, DAA, Tsutomu, additional, and AKIZUKI, Shinichiro, additional
- Published
- 1997
- Full Text
- View/download PDF
109. Microbiological and Clinical Study of Fungemia between 1981 and 1992
- Author
-
YAMAKAMI, Yuriko, primary, TASHIRO, Takayoshi, additional, TOKIMATSU, Issei, additional, NAGAI, Hiroyuki, additional, NAGAOKA, Hiroshi, additional, HASHIMOTO, Atsuro, additional, GOTO, Yoichiro, additional, NASU, Masaru, additional, YAMASAKI, Toru, additional, and ITO, Morio, additional
- Published
- 1995
- Full Text
- View/download PDF
110. A Case of Cytomegalovirus Pneumonia and Pneumocystis carinii Pneumonia with Lung Cancer
- Author
-
TOKIMATSU, Issei, primary, TASHIRO, Takayoshi, additional, MURAKAMI, Junko, additional, ICHIMIYA, Tomoku, additional, HIRAMATSU, Kazufumi, additional, MASUDA, Mitsuru, additional, YAMASAKI, Tohru, additional, NAGAI, Hiroyuki, additional, GOTO, Yoichiro, additional, and NASU, Masaru, additional
- Published
- 1993
- Full Text
- View/download PDF
111. Cloning of the lanosterol 14-α-demethylase ( ERG11) gene in Trichosporon asahii: a possible association between G453 R amino acid substitution and azole resistance in T. asahii.
- Author
-
Kushima, Hisako, Tokimatsu, Issei, Ishii, Hiroshi, Kawano, Rie, Shirai, Ryo, Kishi, Kenji, Hiramatsu, Kazufumi, and Kadota, Jun-ichi
- Subjects
- *
LANOSTEROL , *DEMETHYLASE , *AMINO acids , *FLUCONAZOLE , *AZOLES , *CRYPTOCOCCUS neoformans , *NUCLEOTIDE sequence - Abstract
Lanosterol 14-α-demethylase ( Erg11 protein; Erg11p), encoded by the ERG11 gene, is the primary target of azoles. Recently, a change in affinity of this enzyme for azoles has been reported as a resistance mechanism in several fungal species. Trichosporon asahii ( T. asahii) is susceptible to fluconazole ( FLC). This report identified the ERG11 gene of T. asahii ( NCBI accession; ). The Erg11p of T. asahii, presumed from the DNA sequence, was closely related to the Erg11p of Cryptococcus neoformans. Furthermore, a FLC-susceptible strain was cultured in medium containing FLC at concentrations from 4.0 to 16 μg mL−1 in order to analyze the development of FLC resistance in T. asahii. The degree of resistance was related to the FLC concentration of the growth medium. One highly resistant strain that was cultured in the medium containing 16 μg mL−1 FLC contained 1 point mutation ( G1357 C) that caused a single amino acid substitution at G453 R. This amino acid is highly conserved among major fungal pathogens, and it is in a region very close to the heme-binding domain, which is characteristic of the cytochrome P450 superfamily, the primary target for the azole class of antifungal agents. This amino acid substitution may have caused the high resistance to azoles in T. asahii. [ABSTRACT FROM AUTHOR]
- Published
- 2012
- Full Text
- View/download PDF
112. Deep-seated mycosis: Trichosporonosis.
- Author
-
Tokimatsu, Issei
- Published
- 2012
- Full Text
- View/download PDF
113. A case of empyema caused by Edwardsiella tarda.
- Author
-
Mizunoe, Syunji, Yamasaki, Tohru, Tokimatsu, Issei, Matsunaga, Naoko, Kushima, Hisako, Hashinaga, Kazuhiko, and Kadota, Jun-Ichi
- Subjects
EXUDATES & transudates ,PLEURA diseases ,PLEURAL effusions ,LIVER surgery - Abstract
Summary: In December 2003, a 57-year-old-man was diagnosed as having a hepatic tumor for which he had a hepatectomy. On pathology, the hepatic tumor biopsy specimen was diagnosed as malignant lymphoma. In February 2005, the patient was referred to our hospital because of fever and chest pain. A right pleural effusion was seen on chest X-ray. Microscopic examination of the stained pleural fluid revealed many neutrophils and Gram-negative rods, and Edwardsiella tarda was cultured from the pleural effusion fluid. These findings were consistent with an empyema caused by E. tarda. Therefore, we treated the patient with panipenem/betamipron and thoracic drainage. In this paper, we describe this rare case of empyema caused by E. tarda infection. [Copyright &y& Elsevier]
- Published
- 2006
- Full Text
- View/download PDF
114. The expression of pro- and anti-apoptotic Bcl-2 family proteins in peribronchiolar lymphocytes from patients with diffuse panbronchiolitis.
- Author
-
Kadota, Jun-ichi, Mizunoe, Syunji, Mukae, Hiroshi, Mito, Katsuhiko, Kishi, Kenji, Tokimatsu, Issei, Nagai, Hiroyuki, Tomono, Kazunori, Kohno, Shigeru, and Nasu, Masaru
- Abstract
Summary: Diffuse panbronchiolitis (DPB) is a distinctive form of small airway disease, which is characterized by chronic inflammation with lymphocyte infiltration around bronchioles. The aim of this study was to evaluate the importance of factors related to apoptosis in peribronchiolar lymphocytes of DPB. We employed immunohistochemical methods for the localization of Bax (a promoter of apoptosis), Bcl-2 (an inhibitor of apoptosis), and caspase-3 (a key executioner molecule of apoptosis) in lung tissues of five patients with DPB. In all patients, immunostaining for Bax was almost completely absent in accumulated lymphocytes around the bronchioles and in lymphocytes of the parafollicular area that correspond to a zone populated by T cells. In contrast to the reaction for Bax, Bcl-2 immunoreactivity was uniformly strong in all of the patients. The pattern of staining for caspase-3 was similar to that for Bax in all of the patients. In normal lung tissue, a few lymphocytes showed negative immunostaining for Bcl-2 and a positive reaction for caspase-3. Our results suggest that Bcl-2 protein may provide T-lymphocyte survival and hypercellularity in the bronchioles, thereby contributing to the progression of DPB. [Copyright &y& Elsevier]
- Published
- 2006
- Full Text
- View/download PDF
115. PCR Detection of DNA Specific forTrichosporonSpecies in Serum of Patients with Disseminated Trichosporonosis
- Author
-
Nagai, Hiroyuki, Yamakami, Yuriko, Hashimoto, Atsuro, Tokimatsu, Issei, and Nasu, Masaru
- Abstract
ABSTRACTDeep-seated trichosporonosis is a lethal opportunistic infection that disseminates rapidly and widely in immunocompromised patients, and early diagnosis is crucial for the treatment of this infection. We developed a novel nested-PCR assay that detects DNA specific for clinically important strains of Trichosporonin serum samples from patients with disseminated trichosporonosis. In this assay, two sets of oligonucleotide primers were derived from the sequence of 26S rRNA genes of Trichosporon asahii. The specific fragment was amplified from T. asahiiand T. mucoides, but not from other microorganisms, including some other basidiomycetous fungi (Cryptococcus, Malassezia,Rhodotorula, and Sporobolomyces). Target DNA was detected by the nested PCR with as little as 5 fg of the extracted DNA of T. asahii. In a study using 11 clinical samples, the specific fragment was detected by the nested PCR in 64% (7 of 11) of sera from patients with histologically diagnosed disseminated trichosporonosis, while glucuronoxylomannan antigen was detected in only 54% (6 of 11) of the samples. Our new nested-PCR assay using serum samples can be performed repeatedly throughout the course of the disease. In addition, not only can it be used for early diagnosis of trichosporonosis, but it may also be beneficial for monitoring its progress or response to therapy.
- Published
- 1999
- Full Text
- View/download PDF
116. QUANTITATIVE PCR ASSAY USED TO MONITOR SERUM TRICHOSPORON ASAHIIDNA CONCENTRATIONS IN DISSEMINATED TRICHOSPORONOSIS
- Author
-
Tsuji, Yoichiro, Tokimatsu, Issei, Sugita, Takashi, Nozaki, Masatoshi, Kobayashi, Daisuke, Imai, Kohsuke, Kogawa, Kazuhiro, and Nonoyama, Shigeaki
- Abstract
A bone marrow transplant recipient with disseminated trichosporonosis was successfully treated with voriconazole. Quantitative PCR assay results for Trichosporon asahiiDNA in the sera were well correlated with the patient's clinical course. Based on the in vitro susceptibility test, the organism was susceptible to voriconazole.
- Published
- 2008
- Full Text
- View/download PDF
117. Characterization of influenza infection in a high-income urban setting in Nairobi, Kenya.
- Author
-
Miring'u, Gabriel, Muriithi, Betty, Shoji, Hisashi, Symekher, Samwel M. L., Wandera, Ernest Apondi, Majisu, Claire, Takei, Mitsuo, Mwiraria, Koome, Saito, Yukie, Kaneko, Satoshi, and Tokimatsu, Issei
- Subjects
- *
INFLUENZA , *RECEIVER operating characteristic curves , *VIRUS diseases , *INFLUENZA A virus , *INFLUENZA viruses , *JOINT pain - Abstract
Background: Influenza viruses are an important cause of respiratory infections across all age groups. Information on occurrence and magnitude of influenza virus infections in different populations in Kenya however remains scanty, compromising estimation of influenza disease burden. This study examined influenza infection in an urban high-income setting in Nairobi to establish its prevalence and activity of influenza viruses, and evaluated diagnostic performance of a rapid influenza diagnostic test. Methodology: A cross-sectional hospital-based study was conducted in six private health facilities located within high-income residential areas in Nairobi from January 2019 to July 2020. Patients of all ages presenting with influenza-like illness (ILI) were recruited into the study. Detection of influenza virus was conducted using rapid diagnosis and reverse transcription–polymerase chain reaction (RT–PCR). Data were summarized using descriptive statistics and tests of association. Sensitivity, specificity and area under receiver operating characteristics curve was calculated to establish diagnostic accuracy of the rapid diagnosis test. Results: The study recruited 125 participants with signs and symptoms of ILI, of whom 21 (16.8%) were positive for influenza viruses. Of all the influenza-positive cases, 17 (81.0%) were influenza type A of which 70.6% were pandemic H1N1 (A/H1N1 2009). Highest detection was observed among children aged 5–10 years. Influenza virus mostly circulated during the second half of the year, and fever, general fatigue and muscular and joint pain were significantly observed among participants with influenza virus. Sensitivity and specificity of the diagnostic test was 95% (95% confidence interval 75.1–99.9) and 100% (95% confidence interval 96.5–100.0), respectively. Conclusions: Findings of this study shows continuous but variable activity of influenza virus throughout the year in this population, with substantial disease burden. The findings highlight the need for continuous epidemiologic surveillance including genetic surveillance to monitor activity and generate data to inform vaccine introduction or development, and other interventions. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
118. Antimicrobial susceptibilities and analysis of genes related to penicillin or macrolide resistance in Streptococcus pneumoniae
- Author
-
Hiramatsu, Kazufumi, Ohama, Minoru, Mijajima, Yoshiko, Kishi, Kenji, Mizunoe, Syunji, Tokimatsu, Issei, Nagai, Hiroyuki, Kadota, Jun-ichi, Saikawa, Tetsunori, and Nasu, Masaru
- Subjects
- *
ANTI-infective agents , *PENICILLIN , *STREPTOCOCCUS pneumoniae , *MACROLIDE antibiotics - Abstract
One hundred and seventy-seven strains of Streptococcus pneumoniae derived from respiratory specimens between 1987 and 2001 were evaluated for their antimicrobial susceptibilities and distribution of genes related to penicillin and macrolide resistance. Resistance rates tended to be higher for the 1996–2001 isolates than for the 1987–1995 isolates for all β-lactams tested. For benzylpenicillin the MIC90 value of the isolates derived between 1996 and 2001 was 1.56 mg/L, while that of strains isolated between 1987 and 1990 was 0.05 mg/L. Furthermore, the number of strains susceptible to macrolides also decreased, but only two strains isolated in 1993 were resistant to levofloxacin of the 177 S. pneumoniae strains tested. When of genes relating to penicillin resistance were analysed using PCR with primers specific to susceptible alleles, although more than 50% of strains from 1987 to 1990 and 1991 to 1995 revealed no mutations in the pbp 1a, 2x and 2b genes, only 30.0% of strains derived between 1996 and 2001 showed no mutations in the pbp gene. Strains having mutations in all three pbp genes (1a, 2x and 2b) by the PCR method increased from only 2.2% in the 1987–1990 derived strains to 27.5% in the 1996–2001 strains. Furthermore, 64.1 and 60.0% of the isolates from 1987 to 1990 and 1991 to 1995, respectively, did not possess either the mefA or ermB by PCR analysis. Conversely, 75.0% of isolates from 1996 to 2001 possessed mefA and/or ermB. These genetic changes may explain the increase in the number of penicillin and macrolide resistant strains. We believe that it is important to evaluate changes in MIC as well as genetic mutations in order to select the most appropriate therapy for S. pneumoniae infections. [Copyright &y& Elsevier]
- Published
- 2004
- Full Text
- View/download PDF
119. A case of a geriatric patient with thrombocytopenia after partial recovery from COVID-19.
- Author
-
Hayashi Y, Momo K, Ando M, Koya H, Nagai T, Shinmura K, Tokimatsu I, Akutsu Y, and Kurosawa M
- Subjects
- Humans, Aged, Male, SARS-CoV-2, Fatal Outcome, COVID-19 complications, COVID-19 therapy, Thrombocytopenia etiology
- Abstract
The global emergence of -COVID-19 has prompted rapid therapeutic and vaccine advancements; however, clinical evidence remains limited. With around a 50% fatality rate for COVID-19 patients with acute respiratory distress syndrome (ARDS), early intervention is crucial. This report details a severe case of post-COVID-19 thrombocytopenia in a 79-year-old man and emphasizes its critical nature. Despite negative initial COVID-19 test results, subsequent positive results led to treatment initiation, and severe thrombocytopenia persisted resulting in bleeding complications and death. Recognized as a hematological manifestation of COVID-19, thrombocytopenia in this geriatric patient highlights the need for extended post-COVID-19 monitoring and management. This underscores the importance of vigilance and timely intervention, especially in vulnerable populations, and emphasizes the need for further research to understand the intricate relationship between COVID-19 and thrombocytopenia.
- Published
- 2024
- Full Text
- View/download PDF
120. Antimicrobial therapy and outcome of methicillin-resistant Staphylococcus aureus endocarditis: A retrospective multicenter study in Japan.
- Author
-
Mitsutake K, Shinya N, Seki M, Ohara T, Uemura K, Fukunaga M, Sakai J, Nagao M, Sata M, Hamada Y, Kawasuji H, Yamamoto Y, Nakamatsu M, Koizumi Y, Mikamo H, Ukimura A, Aoyagi T, Sawai T, Tanaka T, Izumikawa K, Takayama Y, Nakamura K, Kanemitsu K, Tokimatsu I, Nakajima K, and Akine D
- Subjects
- Humans, Retrospective Studies, Aged, Male, Female, Japan epidemiology, Middle Aged, Daptomycin therapeutic use, Aged, 80 and over, Linezolid therapeutic use, Prognosis, Treatment Outcome, Vancomycin therapeutic use, Methicillin-Resistant Staphylococcus aureus drug effects, Methicillin-Resistant Staphylococcus aureus isolation & purification, Staphylococcal Infections drug therapy, Staphylococcal Infections mortality, Staphylococcal Infections microbiology, Anti-Bacterial Agents therapeutic use, Hospital Mortality, Endocarditis, Bacterial drug therapy, Endocarditis, Bacterial microbiology, Endocarditis, Bacterial mortality
- Abstract
Background: MRSA (methicillin-resistant Staphylococcus aureus)-infective endocarditis (IE) is associated with high morbidity and mortality. This study aimed to assess data from patients with MRSA-IE across multiple facilities in Japan, with a specific focus on antimicrobial therapy and prognosis., Methods: This retrospective study enrolled patients with a confirmed diagnosis of IE attributed to MRSA, spanning the period from January 2015 to April 2019., Results: Sixty-four patients from 19 centers were included, with a median age of 67 years. The overall mortality rate was 28.1% at 30 days, with an in-hospital mortality of 45.3%. The most frequently chosen initial anti-MRSA agents were glycopeptide in 67.2% of cases. Daptomycin and linezolid were selected as initial therapy in 23.4% and 17.2% of cases, respectively. Approximately 40% of all patients underwent medication changes due to difficulty in controlling infection or drug-related side effects. Significant prognostic factors by multivariable analysis were DIC for 30-day mortality and surgical treatment for 30-day and in-hospital mortality. For vancomycin as initial monotherapy, there was a trend toward a worse prognosis for 30-day and in-hospital mortality (OR, 6.29; 95%CI, 1.00-39.65; p = 0.050, OR, 3.61; 95%CI, 0.93-14.00; p = 0.064). Regarding the choice of initial antibiotic therapy, statistical analysis did not show significant differences in prognosis., Conclusion: Glycopeptide and daptomycin were the preferred antibiotics for the initial therapy of MRSA-IE. Antimicrobial regimens were changed for various reasons. Prognosis was not significantly affected by choice of antibiotic therapy (glycopeptide, daptomycin, linezolid), but further studies are needed to determine which antimicrobials are optimal as first-line agents., Competing Interests: Declaration of Competing interest Tokimatsu I. received scholarship donations from Shionogi Pharmaceuticals, Inc. and Daiichi Sankyo Co. Ltd. Ukimura A. received scholarship donations from Shionogi Pharmaceuticals, Inc. Hiroshige Mikamo received speaker honoraria from MSD K.K., FUJIFILM Toyama Chemical Co., Ltd., Miyarisan Pharmaceutical Co., Daiichi Sankyo Co., Ltd., Pfizer Japan Inc., Sanofi K.K., Sumitomo Pharma Co., Ltd., Kyorin Pharmaceutical Co., Ltd., Shionogi & Co., Ltd. Japan, Kowa Co. Ltd., Gilead Sciences K.K., GSK Group of Companies, Saraya Co. Ltd., Tsumura & Co. Japan, Nippon Becton Dickinson Company, Ltd., and FUKOKU Co., Ltd., grant supports from Asai Kasei Pharma Co., Shionogi & Co., Ltd., Sumitomo Pharma Co., Ltd., and FUKOKU Co., Ltd. Mitsutake K, Shinya N, Seki M, Ohara T, Uemura K, Fukunaga M, Sakai J, Nagao M, Sata M, Hamada Y, Kawasuji H, Yamamoto Y, Nakamatsu M, Koizumi Y, Aoyagi T, Sawai T, Tanaka T, Izumikawa K, Takayama Y, Nakamura K, Kanemitsu K, Nakajima K, and Akine D have no conflict of interest., (Copyright © 2024 Japanese Society of Chemotherapy, Japanese Association for Infectious Diseases, and Japanese Society for Infection Prevention and Control. Published by Elsevier Ltd. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF
121. Clinical characteristics and analysis of prognostic factors in methicillin-resistant Staphylococcus aureus endocarditis: A retrospective multicenter study in Japan.
- Author
-
Mitsutake K, Shinya N, Seki M, Ohara T, Uemura K, Fukunaga M, Sakai J, Nagao M, Sata M, Hamada Y, Kawasuji H, Yamamoto Y, Nakamatsu M, Koizumi Y, Mikamo H, Ukimura A, Aoyagi T, Sawai T, Tanaka T, Izumikawa K, Takayama Y, Nakamura K, Kanemitsu K, Tokimatsu I, Nakajima K, and Akine D
- Subjects
- Humans, Female, Retrospective Studies, Male, Aged, Japan epidemiology, Prognosis, Middle Aged, Aged, 80 and over, Risk Factors, Methicillin-Resistant Staphylococcus aureus isolation & purification, Staphylococcal Infections mortality, Staphylococcal Infections microbiology, Staphylococcal Infections epidemiology, Staphylococcal Infections drug therapy, Staphylococcal Infections diagnosis, Endocarditis, Bacterial microbiology, Endocarditis, Bacterial mortality, Endocarditis, Bacterial epidemiology, Endocarditis, Bacterial diagnosis, Endocarditis, Bacterial drug therapy, Hospital Mortality, Anti-Bacterial Agents therapeutic use, Cross Infection microbiology, Cross Infection mortality, Cross Infection epidemiology, Cross Infection drug therapy
- Abstract
Background: Infective endocarditis (IE) caused by MRSA (methicillin-resistant Staphylococcus aureus) is associated with a high mortality rate. This study aimed to elucidate the characteristics of patients with MRSA-IE in Japan and identify the factors associated with prognosis., Methods: This retrospective study included patients with a confirmed diagnosis of IE caused by MRSA, between January 2015 and April 2019., Results: A total of 65 patients from 19 centers were included, with a mean age of 67 years and 26 % were female. Fifty percent of the patients with IE were had nosocomial infections and 25 % had prosthetic valve involvement. The most common comorbidities were hemodialysis (20 %) and diabetes (20 %). Congestive heart failure was present in 86 % of patients (NYHA class I, II: 48 %; III, IV: 38 %). The 30-day and in-hospital mortality rates were 29 % and 46 %, respectively. Multi-organ failure was the primary cause of death, accounting for 43 % of all causes of death. Prognostic factors for in-hospital mortality were age, disseminated intravascular coagulation, daptomycin and/or linezolid as initial antibiotic therapy, and surgery. Surgical treatment was associated with a lower mortality rate (odds ratio [OR], 0.026; 95 % confidence interval [CI], 0.002-0.382; p = 0.008 for 30-day mortality and OR, 0.130; 95 % CI; 0.029-0.584; p = 0.008 for in-hospital mortality)., Conclusion: Mortality due to MRSA-IE remains high. Surgical treatment is a significant prognostic predictor of MRSA-IE., Competing Interests: Declaration of competing interest Tokimatsu I. received scholarship donations from Shionogi Pharmaceuticals, Inc. and Daiichi Sankyo Co., Ltd. Ukimura A. received scholarship donations from Shionogi Pharmaceuticals Inc. Hiroshige Mikamo received speaker honoraria from MSD K.K., FUJIFILM Toyama Chemical Co., Ltd., Miyarisan Pharmaceutical Co., Daiichi Sankyo Co., Ltd., Pfizer Japan Inc., Sanofi K.K., Sumitomo Pharma Co., Ltd., Kyorin Pharmaceutical Co., Ltd., Shionogi & Co., Japan. Ltd., Kowa Co. Ltd., Gilead Sciences K.K., the GSK Group of Companies, Saraya Co. Ltd., and Tsumura and Co. Japan, Nippon Becton Dickinson Company, Ltd., and FUKOKU Co., Ltd., and grant support from Asai Kasei Pharma Co., Shionogi & Co., Ltd., Sumitomo Pharma Co., Ltd., and FUKOKU Co., Ltd. Mitsutake K, Shinya N, Seki M, Ohara T, Uemura K, Fukunaga M, Sakai J, Nagao M, Sata M, Hamada Y, Kawasuji H, Yamamoto Y, Nakamatsu M, Koizumi Y, Aoyagi T, Sawai T, Tanaka T, Izumikawa K, Takayama Y, Nakamura K, Kanemitsu K, Nakajima K, and Akine D have no conflict of interest., (Copyright © 2024 Japanese Society of Chemotherapy, Japanese Association for Infectious Diseases, and Japanese Society for Infection Prevention and Control. Published by Elsevier Ltd. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF
122. Nationwide surveillance of bacterial respiratory pathogens conducted by the surveillance committee of the Japanese Society of Chemotherapy, the Japanese Association for Infectious Diseases, and the Japanese Society for Clinical Microbiology in 2019-2020: General view of the pathogens' antibacterial susceptibility.
- Author
-
Tokimatsu I, Matsumoto T, Tsukada H, Fujikura Y, Miki M, Morinaga Y, Sato J, Wakamura T, Kiyota H, Tateda K, Yanagisawa H, Sasaki T, Ikeda H, Horikawa H, Takahashi H, Seki M, Mori Y, Takeda H, Kurai D, Hasegawa N, Uwamino Y, Kudo M, Yamamoto M, Nagano Y, Nomura S, Tetsuka T, Hosokai M, Aoki N, Yamamoto Y, Iinuma Y, Mikamo H, Suematsu H, Maruyama T, Kawabata A, Sugaki Y, Nakamura A, Fujikawa Y, Fukumori T, Ukimura A, Kakeya H, Niki M, Yoshida K, Kobashi Y, Tokuyasu H, Yatera K, Ikegami H, Fujita M, Matsumoto T, Yanagihara K, Matsuda J, Hiramatsu K, and Shinzato T
- Subjects
- Adult, Humans, Ampicillin, Anti-Bacterial Agents pharmacology, Anti-Bacterial Agents therapeutic use, Bacteria, beta-Lactamases, Drug Resistance, Bacterial, Haemophilus influenzae, Microbial Sensitivity Tests, Japan, Communicable Diseases drug therapy, Methicillin-Resistant Staphylococcus aureus, Respiratory Tract Infections drug therapy, Respiratory Tract Infections epidemiology, Respiratory Tract Infections microbiology
- Abstract
The trends and prevalence of antimicrobial susceptibility of pathogens vary by country, region, and time. Long-term regular surveillance is required to investigate trends in the antimicrobial resistance of various isolated bacterial pathogens. We report the results of a nationwide surveillance on the antimicrobial susceptibility of bacterial respiratory pathogens in Japan conducted by the Japanese Society of Chemotherapy, the Japanese Association for Infectious Diseases, and the Japanese Society for Clinical Microbiology. The isolates were collected from clinical specimens obtained from adult patients who visited a collaborating medical facility between June 2019 and December 2020 and were diagnosed with respiratory tract infections by a physician. Antimicrobial susceptibility testing was performed in a centralized laboratory according to the methods recommended by the Clinical and Laboratory Standards Institute. Susceptibility testing was performed for 932 strains (201 Staphylococcus aureus, 158 Streptococcus pneumoniae, 6 S. pyogenes, 136 Haemophilus influenzae, 127 Moraxella catarrhalis, 141 Klebsiella pneumoniae, and 163 Pseudomonas aeruginosa) collected from 32 facilities in Japan. The proportions of methicillin-resistant S. aureus and penicillin-resistant S. pneumoniae were 35.3% and 0%, respectively. In H. influenzae, 16.2% and 16.9% were β-lactamase-producing ampicillin resistant and β-lactamase-negative ampicillin resistant, respectively. Extended-spectrum β-lactamase-producing K. pneumoniae accounted for 5.0% of all K. pneumoniae infections. Carbapenemase-producing K. pneumoniae and multi-drug-resistant P. aeruginosa with metallo-β-lactamase were not detected in this study. This surveillance will be a useful reference for treating respiratory infections in Japan and will provide evidence to enhance the appropriate use of antimicrobial agents., Competing Interests: Declaration of competing interest Issei Tokimatsu received research funding from Asahi Kasei Pharma Corporation, and scholarship donations from Shionogi & Co., Ltd., and Daiichi Sankyo Co., Ltd. Tetsuya Matsumoto received speaker honoraria from MSD K.K., and Pfizer Japan Inc. Makoto Miki hold shares in Daiichi Sankyo Co., Ltd., and received speaker honoraria from Kyorin Pharmaceutical Co., Ltd. Tomotaro Wakamura is an employee of Sumitomo Pharma Co., Ltd. Daisuke Kurai received research funding from Daiichi Sankyo Co., Ltd., and scholarship donations from Shionogi & Co., Ltd. Hiroki Tsukada received speaker honoraria from Kyorin Pharmaceutical Co., Ltd. Nobuki Aoki received speaker honoraria from Kyorin Pharmaceutical Co., Ltd. Hiroshige Mikamo received speaker honoraria from Nippon Becton Dickinson Company, Ltd., Astellas Pharma Inc., Sumitomo Pharma Co., Ltd. (formerly Sumitomo Dainippon Pharma Co., Ltd.), Pfizer Japan Inc., MSD K.K., Daiichi Sankyo Co., Ltd., Fujifilm Toyama Chemical Co., Ltd., Miyarisan Pharmaceutical Co. Ltd., Kyorin Pharmaceutical Co., Ltd., Gilead Sciences K.K., Saraya Co., Ltd., Tsumura & Co., Meiji Seika Pharma Co., Ltd., Sanofi K.K., Shionogi & Co., Ltd., Fukoku Co., Ltd., GlaxoSmithKline K.K., Kowa Company, Ltd., research funding from Fukoku Co., Ltd., Sekisui Medical Co., Ltd., Meiji Seika Pharma Co., Ltd., Pfizer Japan Inc., Saraya Co., Ltd., Miyarisan Pharmaceutical Co. Ltd., Roche Diagnostics K.K., ASKA Pharmaceutical Co., Ltd., Tosoh Corporation, Bruker Japan K.K., Abbott Diagnostics Medical Co., Ltd., Ortho Clinical Diagnostics K.K., Kyorin Pharmaceutical Co., Ltd., and scholarship donations from Asahi Kasei Pharma Co., Shionogi & Co., Ltd., Daiichi Sankyo Co., Ltd., Fujifilm Toyama Chemical Co., Ltd., Sumitomo Pharma Co., Ltd. (formerly Sumitomo Dainippon Pharma Co., Ltd.), Fukoku Co., Ltd., and Morii Co., Ltd. Atsushi Nakamura received speaker honoraria from Kyorin Pharmaceutical Co., Ltd., MSD K.K., Astellas Pharma Inc. Akira Ukimura received scholarship donations from Shionogi & Co., Ltd. Hiroshi Kakeya received speaker honoraria from MSD K.K., Sumitomo Pharma Co., Ltd. (formerly Sumitomo Dainippon Pharma Co., Ltd.), Shionogi & Co., Ltd., Asahi Kasei Pharma Corporation., Astellas Pharma Inc., and Pfizer Japan Inc. Katsunori Yanagihara received speaker honoraria from Daiichi Sankyo Co., Ltd., MSD K.K., Astellas Pharma Inc., and Taisho Pharma Co., Ltd. (formerly Taisho Toyama Pharmaceutical Co., Ltd.), research funding from Fujifilm Toyama Chemical Co., Ltd., Meiji Seika Pharma Co., Ltd., Kyorin Pharmaceutical Co., Ltd., and Shionogi & Co., Ltd., and scholarship donations from Sumitomo Pharma Co., Ltd. (formerly Sumitomo Dainippon Pharma Co., Ltd.), Fujifilm Toyama Chemical Co., Ltd., Taiho Pharmaceutical Co., Ltd., and Kyorin Pharmaceutical Co., Ltd., (Copyright © 2023 Japanese Society of Chemotherapy, Japanese Association for Infectious Diseases, and Japanese Society for Infection Prevention and Control. Published by Elsevier Ltd. All rights reserved.)
- Published
- 2023
- Full Text
- View/download PDF
123. Genetic epidemiology using whole genome sequencing and haplotype networks revealed the linkage of SARS-CoV-2 infection in nosocomial outbreak.
- Author
-
Ishikawa F, Udaka Y, Oyamada H, Ishino K, Tokimatsu I, Sagara H, and Kiuchi Y
- Abstract
Background: A characteristic feature of SARS-CoV-2 is its ability to transmit from pre- or asymptomatic patients, complicating the tracing of infection pathways and causing outbreaks. Despite several reports that whole genome sequencing (WGS) and haplotype networks are useful for epidemiologic analysis, little is known about their use in nosocomial infections., Aim: We aimed to demonstrate the advantages of genetic epidemiology in identifying the link in nosocomial infection by comparing single nucleotide variations (SNVs) of isolates from patients associated with an outbreak in Showa University Hospital., Methods: We used specimens from 32 patients in whom COVID-19 had been diagnosed using clinical reverse transcription-polymerase chain reaction tests. RNA of SARS-CoV-2 from specimens was reverse-transcribed and analysed using WGS. SNVs were extracted and used for lineage determination, phylogenetic tree analysis, and median-joining analysis., Findings: The lineage of SARS-CoV-2 that was associated with outbreak in Showa University Hospital was B.1.1.214, which was consistent with that found in the Kanto metropolitan area during the same period. Consistent with canonical epidemiological observations, haplotype network analysis was successful for the classification of patients. Additionally, phylogenetic tree analysis revealed three independent introductions of the virus into the hospital during the outbreak. Further, median-joining analysis indicated that four patients were directly infected by any of the others in the same cluster., Conclusion: Genetic epidemiology with WGS and haplotype networks is useful for tracing transmission and optimizing prevention strategies in nosocomial outbreaks., (© 2021 The Authors.)
- Published
- 2021
- Full Text
- View/download PDF
124. Successful Treatment of Breakthrough Trichosporon asahii Fungemia by the Combination Therapy of Fluconazole and Liposomal Amphotericin B in a Patient with Follicular Lymphoma.
- Author
-
Itoh K, Iwasaki H, Negoro E, Shigemi H, Tokimatsu I, Tsutani H, and Yamauchi T
- Subjects
- Amphotericin B therapeutic use, Antifungal Agents therapeutic use, Basidiomycota, Fluconazole therapeutic use, Humans, Middle Aged, Fungemia drug therapy, Lymphoma, Follicular drug therapy, Trichosporon, Trichosporonosis drug therapy
- Abstract
Invasive trichosporonosis is a rare and lethal fungal infection that occurs in immunocompromised patients. Breakthrough trichosporonosis can occur in patients treated with echinocandins since Trichosporon spp. are resistant to these antifungal agents. We report a case of breakthrough Trichosporon asahii fungemia. A 62-year-old Japanese woman with relapsed follicular lymphoma was treated empirically with broad-spectrum antibiotics and micafungin due to an intermittent fever during reinduction chemotherapy. After four cycles of anti-cancer chemotherapy, she experienced a high neutropenic fever and T. asahii was subsequently detected from a blood culture. The patient was not given voriconazole due to the contraindication for use with carbamazepine, and she was successfully treated with fluconazole plus liposomal amphotericin B without any serious complications. The combined therapy of fluconazole and liposomal amphotericin B may therefore be useful in treating T. asahii fungemia, especially in patients receiving antiepileptic agents.
- Published
- 2021
- Full Text
- View/download PDF
125. Nationwide surveillance of bacterial respiratory pathogens conducted by the surveillance committee of japanese society of chemotherapy, the japanese association for infectious diseases, and the japanese society for clinical microbiology in 2016: General view of the pathogens' antibacterial susceptibility.
- Author
-
Yanagihara K, Matsumoto T, Tokimatsu I, Tsukada H, Fujikura Y, Miki M, Morinaga Y, Sato J, Wakamura T, Kiyota H, Tateda K, Hanaki H, Fujiuchi S, Takahashi M, Kayaba H, Mori Y, Takeda H, Ikeda H, Takahashi H, Konno M, Niitsuma K, Niki Y, Takuma T, Kawana A, Kudo M, Hirano T, Miyazawa N, Aso S, Aoki N, Honma Y, Yamamoto Y, Iinuma Y, Mikamo H, Yamagishi Y, Nakamura A, Kondo S, Kawabata A, Sugaki Y, Yamamoto T, Nishi I, Hamaguchi S, Kakeya H, Fujikawa Y, Mitsuno N, Ukimura A, Yoshida K, Hayashi M, Mikasa K, Kasahara K, Tokuyasu H, Hino S, Shimizu E, Chikumi H, Fujita M, Kadota J, Hiramatsu K, Suga M, and Muranaka H
- Subjects
- Adult, Anti-Bacterial Agents pharmacology, Anti-Bacterial Agents therapeutic use, Drug Resistance, Bacterial, Haemophilus influenzae, Humans, Japan epidemiology, Microbial Sensitivity Tests, Communicable Diseases drug therapy, Methicillin-Resistant Staphylococcus aureus, Respiratory Tract Infections drug therapy, Respiratory Tract Infections epidemiology
- Abstract
The nationwide surveillance on antimicrobial susceptibility of bacterial respiratory pathogens from the patients in Japan was conducted by the Japanese Society of Chemotherapy, the Japanese Association for Infectious Diseases, and the Japanese Society for Clinical Microbiology in 2016. The isolates were collected from clinical specimens obtained from well-diagnosed adult patients with respiratory tract infections during the period between February 2016 and August 2016 by three societies. Antimicrobial susceptibility testing was conducted at the central reference laboratory according to the method recommended by Clinical Laboratory Standards Institute. Susceptibility testing was evaluated in 1062 strains (143 Staphylococcus aureus, 210 Streptococcus pneumoniae, 17 Streptococcus pyogenes, 248 Haemophilus influenzae, 151 Moraxella catarrhalis, 134 Klebsiella pneumoniae, and 159 Pseudomonas aeruginosa). Ratio of methicillin-resistant S. aureus was 48.3%, and those of penicillin-susceptible S. pneumoniae was 99.5%. Among H. influenzae, 14.1% of them were found to be β-lactamase-producing ampicillin-resistant strains, and 41.1% to be β-lactamase-non-producing ampicillin-resistant strains. Extended spectrum β-lactamase-producing K. pneumoniae and multi-drug resistant P. aeruginosa with metallo β-lactamase were 4.5% and 0.6%, respectively., Competing Interests: Declaration of competing interest Katsunori Yanagihara received speaker honoraria from Taisho Toyama Pharmaceutical Co., Ltd., Pfizer Japan Inc., MSD K.K., Astellas Pharma Inc., Daiichi Sankyo Co., Ltd., Nippon Becton Dickinson Company, Ltd., and bioMerieux Japan Ltd., and received scholarship donations from Toyama Chemical Co., Ltd., Sumitomo Dainippon Pharma Co., Ltd., Daiichi Sankyo Co., Ltd., Pfizer Japan Inc., MSD K.K., Taiho Pharmaceutical Co., Ltd., and FUJIFILM Toyama Chemical Co., Ltd. and received research funds from Nippon Becton Dickinson Company, Ltd., Shionogi, Kyorin Pharmaceutical Co., Ltd., Tosoh Corporation, Miyarisan Pharmaceutical Co., Ltd., and FUJIFILM Toyama Chemical Co., Ltd. Tetsuya Matsumoto received speaker honoraria from MSD K·K., and Pfizer Japan Inc. Makoto Miki received speaker honoraria from Kyorin Pharmaceutical Co., Ltd. Yoshitomo Morinaga received research funds from Nippon Becton Dickinson Company, Ltd., Shionogi & Co., Ltd., Kyorin Pharmaceutical Co., Ltd., Tosoh Corporation, Miyarisan Pharmaceutical Co., Ltd., Roche Diagnostics K·K., Beckman Coulter Inc., Parexel International Co., Ltd., and FUJIFILM Toyama Chemical Co., Ltd. Issei Tokimatsu received scholarship donations from Astellas Pharma Inc., Daiichi Sankyo Co., Ltd., and Shionogi & Co., Ltd. Hiroshi Kiyota have received scholarship donations from Taisho Toyama Pharmaceutical Co., Ltd., Toyama Chemical Co., Ltd., Daiichi Sankyo Co., Ltd., Astellas Pharma Inc., Taiho Pharmaceutical Co., Ltd., and Sanofi K·K. Yoshihito Niki received speaker honoraria from Pfizer Japan Inc., MSD K·K., Astellas Pharma Inc., Taisho Toyama Pharmaceutical Co., Ltd., MSD K·K., Sumitomo Dainippon Pharma Co., Ltd., and Asahi Kasei Pharma Corporation, and received scholarship donations from Astellas Pharma Inc., Daiichi Sankyo Co., Ltd., Taiho Pharmaceutical Co., Ltd., MSD K·K., and Shionogi & Co., Ltd. Takahiro Takuma received scholarship donations from Astellas Pharma Inc., Daiichi Sankyo Co., Ltd., and Shionogi & Co., Ltd. Nobuki Aoki received speaker honoraria from Kyorin Pharmaceutical Co., Ltd. Yoshihiro Yamamoto received research fund from Pfizer Japan Inc. Yoshitsugu Iinuma received speaker honoraria from MSD K·K. Atsushi Nakamura received speaker honoraria from MSD K·K., Kyorin Pharmaceutical Co., Ltd., and Astellas Pharma Inc. Hiroshi Kakeya received speaker honoraria from MSD K·K., Pfizer Japan Inc., Sumitomo Dainippon Pharma Co., Ltd., and Astellas Pharma Inc. Koichiro Yoshida received speaker honoraria from MSD K·K. Junichi Kadota received speaker honoraria from MSD K·K., Nippon Boehringer Ingelheim Co., Ltd., and Astrazeneca Co., Ltd., and received research funds from Taisho Toyama Pharmaceutical Co., Ltd., MSD K·K., and Nippon Boehringer Ingelheim Co., Ltd., and received scholarship donation from Daiichi Sankyo Co., Ltd., (Copyright © 2020. Published by Elsevier Ltd.)
- Published
- 2020
- Full Text
- View/download PDF
126. Antibiotic de-escalation therapy in patients with community-acquired nonbacteremic pneumococcal pneumonia.
- Author
-
Uda A, Tokimatsu I, Koike C, Osawa K, Shigemura K, Kimura T, Miyara T, and Yano I
- Subjects
- Aged, Aged, 80 and over, Anti-Bacterial Agents adverse effects, Anti-Bacterial Agents economics, Drug Costs, Female, Hospitals, University, Humans, Japan, Length of Stay statistics & numerical data, Male, Middle Aged, Practice Guidelines as Topic, Retrospective Studies, Anti-Bacterial Agents administration & dosage, Community-Acquired Infections drug therapy, Pneumonia, Pneumococcal drug therapy
- Abstract
Background De-escalation therapy is recommended as an effective antibiotic treatment strategy for several infectious diseases. While there is limited evidence supporting its clinical and cost-effective outcomes in patients with community-acquired bacteremic pneumonia, there is no evidence in patients with nonbacteremic pneumonia. Objective This study aimed to evaluate the antibiotic costs in patients who did and did not receive de-escalation therapy, based on the 2017 Japanese guidelines for the management of community-acquired nonbacteremic pneumococcal pneumonia of the Japanese Respiratory Society (JRS). Setting Kobe university hospital, Japan. Methods A retrospective case series review including antibiotic use and length of hospital stay was conducted using the medical records from April 2008 to May 2019 at a university hospital in Japan. Main outcome measure Impact of antibiotic de-escalation therapy on the antibiotic costs. Results Among 55 patients who were eligible, the treating physicians de-escalated antibiotics in 28 (51%). The differences in the median length of hospital stay and the incidence of adverse drug reactions between the two groups were not statistically significant (p = 0.67 and 1.0, respectively). However, the median total antibiotic cost per infected patient in the de-escalated group was significantly lower than that in the non-de-escalated group [$269.8 ($195-$389) vs. $420.5 ($221-$799), p = 0.048]. Conclusion Antibiotic de-escalation based on the 2017 JRS guidelines leads to a reduction in total antibiotic costs for the management of community-acquired nonbacteremic pneumococcal pneumonia.
- Published
- 2019
- Full Text
- View/download PDF
127. Efficacy of educational intervention on reducing the inappropriate use of oral third-generation cephalosporins.
- Author
-
Uda A, Kimura T, Nishimura S, Ebisawa K, Ohji G, Kusuki M, Yahata M, Izuta R, Sakaue T, Nakamura T, Koike C, Tokimatsu I, Yano I, Iwata K, and Miyara T
- Subjects
- Japan, Anti-Bacterial Agents therapeutic use, Cephalosporins therapeutic use, Drug Resistance, Bacterial, Hospitals, University statistics & numerical data, Inappropriate Prescribing prevention & control
- Abstract
Purpose: This study aimed to evaluate the efficacy of an educational intervention on reducing the inappropriate use of oral third-generation cephalosporins, the prevalence of resistant bacteria, and clinical outcomes., Methods: A before-after study was conducted to compare the data for 1 year before and after intervention at a Japanese university hospital. Educational intervention included lectures for all medical staff on oral antibiotics and educational meetings with each medical department. The primary outcome was the use of oral third-generation cephalosporins in inpatients as measured by the monthly median days of therapy (DOTs) per 1000 patient days. Secondary outcomes included the use of each oral antibiotic in inpatients and outpatients, proportion of β-lactamase-nonproducing ampicillin-resistant Haemophilus influenzae (BLNAR), penicillin-resistant Streptococcus pneumoniae (PRSP) and extended-spectrum β-lactamase producing Escherichia coli (ESBLEC), the incidence of hospital-acquired Clostridioides difficile infection (HA-CDI), and hospital mortality., Results: The use of oral third-generation cephalosporins in inpatients was significantly decreased after intervention [DOTs (interquartile range): 24.2 (23.5-25.1) vs. 3.7 (0.0-7.1), P < 0.001], and the value in outpatients was also decreased significantly. The use of fluoroquinolones and macrolides did not increase after intervention. The proportion of BLNAR, PRSP and ESBLEC did not change significantly during the study period. The incidence of HA-CDI was significantly decreased, and hospital mortality did not change after intervention., Conclusion: Educational intervention was effective in reducing the use of oral third-generation cephalosporins without increasing the use of broad-spectrum antibiotics and worsening clinical outcome. The prevalence of resistant bacteria did not change during the study period.
- Published
- 2019
- Full Text
- View/download PDF
128. Invasive Scopulariopsis alboflavescens infection in patient with acute myeloid leukemia.
- Author
-
Kurata K, Nishimura S, Ichikawa H, Sakai R, Mizutani Y, Takenaka K, Kakiuchi S, Miyata Y, Kitao A, Yakushijin K, Kawamoto S, Yamamoto K, Ito M, Matsuoka H, Tokimatsu I, Kamei K, and Minami H
- Subjects
- Female, Humans, Immunocompromised Host, Leukemia, Myeloid, Acute microbiology, Mycoses etiology, Mycoses microbiology, Pneumonia microbiology, Young Adult, Leukemia, Myeloid, Acute complications, Pneumonia etiology, Scopulariopsis pathogenicity
- Abstract
Scopulariopsis alboflavescens is a soil saprophyte that is widely distributed in nature. Recently, there have been increasing number of reports of invasive infections with Scopulariopsis species in immunocompromised patients. In this report, we described an adult woman with acute myeloid leukemia and who developed S. alboflavescens pneumonia. Liposomal amphotericin B and voriconazole combination therapy was unsuccessful and the patient died because of pneumonia. Scopulariopsis is highly resistant to available antifungal agents and almost invariably fatal. This case report should alert clinicians to the importance of listing Scopulariopsis as a pathogenic fungus in immunocompromised patients.
- Published
- 2018
- Full Text
- View/download PDF
129. Molecular epidemiologic study of Clostridium difficile infections in university hospitals: Results of a nationwide study in Japan.
- Author
-
Tokimatsu I, Shigemura K, Osawa K, Kinugawa S, Kitagawa K, Nakanishi N, Yoshida H, Arakawa S, and Fujisawa M
- Subjects
- ADP Ribose Transferases genetics, Adolescent, Adult, Aged, Aged, 80 and over, Bacterial Proteins genetics, Clostridioides difficile drug effects, Clostridioides difficile isolation & purification, Clostridium Infections drug therapy, Clostridium Infections microbiology, Epidemiological Monitoring, Feces microbiology, Female, Humans, Inhibitory Concentration 50, Japan epidemiology, Male, Metronidazole therapeutic use, Microbial Sensitivity Tests, Middle Aged, Molecular Epidemiology, Polymerase Chain Reaction, Ribotyping methods, Severity of Illness Index, Vancomycin pharmacology, Vancomycin therapeutic use, Young Adult, Anti-Bacterial Agents therapeutic use, Clostridioides difficile genetics, Clostridium Infections epidemiology, Hospitals, University statistics & numerical data
- Abstract
We conducted a nationwide molecular epidemiological study of Clostridium difficile infection (CDI) in Japan investigated the correlation between the presence of binary toxin genes and CDI severity. This is the first report on molecular epidemiological analyses for CDI in multiple university hospitals in Japan, to our knowledge. We examined 124,484 hospitalized patients in 25 national and public university hospitals in Japan between December 2013 and March 2014, investigating antimicrobial susceptibilities and toxin-related genes for C. difficile isolates from stools. Epidemiological genetic typing was performed by PCR-ribotyping and repetitive sequence-based (rep)-PCR to examine the genetic similarities. The results detected toxin A-positive, toxin B-positive, binary toxin-negative (A
+ B+ CDT- ) detected from 135 isolates (80.8%) and toxin A-negative, toxin B-positive, binary toxin-negative (A- B+ CDT- ) in 23 (13.8%). Toxin A-positive, toxin B-positive, and binary toxin-positive (A+ B+ CDT+ ) were seen in 9 isolates (5.4%). Vancomycin (n = 81, 37.7%) or metronidazole (n = 88, 40.9%) therapies were undertaken in analyzed cases. Ribotypes detected from isolates were 017/subgroup 1, 070, 078, 126, 176, 449, 475/subgroup 1, 499, 451, 566 and newtypes. Rep-PCR classified 167 isolates into 28 cluster groups including 2-15 isolates. In addition, 2 pairs of strains isolated from different institutions belonged to the same clusters. Seven out of 9 (77.8%) of the patients with binary toxin producing strains had "mild to moderate" outcome in evaluated symptoms. In conclusion, we found that binary toxin did not show regional specificity and had no relevance to severity of CDI., (Copyright © 2018 Japanese Society of Chemotherapy and The Japanese Association for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.)- Published
- 2018
- Full Text
- View/download PDF
130. Risk factors for death from Stenotrophomonas maltophilia bacteremia.
- Author
-
Osawa K, Shigemura K, Kitagawa K, Tokimatsu I, and Fujisawa M
- Subjects
- Adolescent, Adult, Aged, Aged, 80 and over, Anti-Bacterial Agents therapeutic use, Child, Child, Preschool, Drug Resistance, Bacterial, Female, Gram-Negative Bacterial Infections drug therapy, Hospitalization statistics & numerical data, Humans, Infant, Infant, Newborn, Intensive Care Units statistics & numerical data, Japan epidemiology, Male, Microbial Sensitivity Tests, Middle Aged, Prospective Studies, Respiration, Artificial statistics & numerical data, Retrospective Studies, Risk Factors, Stenotrophomonas maltophilia drug effects, Stenotrophomonas maltophilia physiology, Survivors statistics & numerical data, Young Adult, Anti-Bacterial Agents pharmacology, Gram-Negative Bacterial Infections mortality, Hospital Mortality trends, Stenotrophomonas maltophilia immunology
- Abstract
Purpose: Stenotrophomonas maltophilia has low pathogenicity potential, but if it causes bacteremia it can be fatal, because it has shown high resistance to many antibiotics and can be difficult to treat. Patient death from S. maltophilia bacteremia has increased since 2014 in our hospital. In this study, we investigated risk factors for death due to S. maltophilia bacteremia., Methods: Seventy patients from the hospital database with S. maltophilia bacteremia between January 2010 and July 2017 were investigated. We retrospectively analyzed risk factors including gender, age, wards, hospitalized duration, clinical history, devices, source of S. maltophilia identification, polymicrobial bacteremia, prior antimicrobial therapy, antimicrobial therapy after bacteremia, and resistance to antibiotics. The statistical analysis was performed to compare the period from 2010 to 2013 to from 2014 to 2017., Results: Comparing the 2010-2013 period to the 2014-2017 period, it revealed that history of hospitalization, identification of S. maltophilia from sputum, polymicrobial bacteremia, prior carbapenem use, and mortality was significantly different in S. maltophilia bacteremia (p = 0.028, p = 0.004, p < 0.001, p = 0.034, and p = 0.007, respectively). Comparison between non-survivors and survivors for 2010-2013 and 2014-2017 found ICU admission and ventilator use were seen more often in non-survivors (p = 0.030 vs p = 0.013 and p = 0.027 vs p = 0.010, respectively)., Conclusions: Our analyses showed increase in mortality from S. maltophilia bacteremia from 2014 to 2017, and that non-survivors had a higher frequency of ICU admission and ventilator use in both the 2010-2013 and 2014-2017 periods. There were more combination antimicrobial therapy cases after bacteremia in 2014-2017. Further prospective studies with larger numbers of patients should be undertaken for definitive conclusions., (Copyright © 2018 Japanese Society of Chemotherapy and The Japanese Association for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.)
- Published
- 2018
- Full Text
- View/download PDF
131. Determination of the antimicrobial susceptibility and molecular profile of clarithromycin resistance in the Mycobacterium abscessus complex in Japan by variable number tandem repeat analysis.
- Author
-
Kusuki M, Osawa K, Arikawa K, Tamura M, Shigemura K, Shirakawa T, Nakamura T, Nakamachi Y, Fujisawa M, Saegusa J, and Tokimatsu I
- Subjects
- Adult, Aged, Aged, 80 and over, DNA, Bacterial chemistry, DNA, Bacterial genetics, DNA, Ribosomal chemistry, DNA, Ribosomal genetics, Female, Humans, Japan, Male, Middle Aged, Molecular Diagnostic Techniques methods, Mycobacterium Infections, Nontuberculous microbiology, RNA, Ribosomal, 23S genetics, Anti-Bacterial Agents pharmacology, Clarithromycin pharmacology, Drug Resistance, Bacterial, Microbial Sensitivity Tests methods, Minisatellite Repeats, Mycobacterium abscessus drug effects, Mycobacterium abscessus genetics
- Abstract
Mycobacterium abscessus complex, including three subspecies-M. abscessus, M. massiliense, and M. bolletii-is resistant to a variety of antibiotics so limited treatment options are available. The susceptibility of these subspecies to antimicrobial agents depends in particular on the erm(41) sequevar and rrl mutations in the 23S rRNA, which are potentially related to clarithromycin (CLR) resistance. The purpose of this study was to carry out identification and molecular characterization of these subspecies based on variable number of tandem repeats (VNTR) analysis. Twenty-four M. abscessus complex strains were identified as M. abscessus and M. massiliense and these subspecies could be discriminated between based on their resistance to CLR, as determined by truncation or mutation of erm(41) or mutation of rrl, as illustrated by their VNTR patterns. In conclusion, we confirmed that the CLR susceptibility profiles could be differentiated according to the subspecies of M. abscessus complex strains by their VNTR patterns., (Copyright © 2018. Published by Elsevier Inc.)
- Published
- 2018
- Full Text
- View/download PDF
132. Long-term efficacy of comprehensive multidisciplinary antibiotic stewardship programs centered on weekly prospective audit and feedback.
- Author
-
Kimura T, Uda A, Sakaue T, Yamashita K, Nishioka T, Nishimura S, Ebisawa K, Nagata M, Ohji G, Nakamura T, Koike C, Kusuki M, Ioroi T, Mukai A, Abe Y, Yoshida H, Hirai M, Arakawa S, Yano I, Iwata K, and Tokimatsu I
- Subjects
- Clostridiales, Commission on Professional and Hospital Activities, Controlled Before-After Studies, Feedback, Humans, Interdisciplinary Communication, Japan epidemiology, Methicillin-Resistant Staphylococcus aureus, Pseudomonas aeruginosa, Treatment Outcome, Antimicrobial Stewardship, Bacterial Infections drug therapy, Bacterial Infections epidemiology
- Abstract
Objective: To evaluate the long-term effects of comprehensive antibiotic stewardship programs (ASPs) on antibiotic use, antimicrobial-resistant bacteria, and clinical outcomes., Design: Before-after study., Setting: National university hospital with 934 beds., Intervention: Implementation in March 2010 of a comprehensive ASPs including, among other strategies, weekly prospective audit and feedback with multidisciplinary collaboration., Methods: The primary outcome was the use of antipseudomonal antibiotics as measured by the monthly mean days of therapy per 1000 patient days each year. Secondary outcomes included overall antibiotic use and that of each antibiotic class, susceptibility of Pseudomonas aeruginosa, the proportion of patients isolated methicillin-resistant Staphylococcus aureus (MRSA) among all patients isolated S. aureus, the incidence of MRSA, and the 30-day mortality attributable to bacteremia., Results: The mean monthly use of antipseudomonal antibiotics significantly decreased in 2011 and after as compared with 2009. Susceptibility to levofloxacin was significantly increased from 2009 to 2016 (P = 0.01 for trend). Its susceptibility to other antibiotics remained over 84% and did not change significantly during the study period. The proportion of patients isolated MRSA and the incidence of MRSA decreased significantly from 2009 to 2016 (P < 0.001 and = 0.02 for trend, respectively). There were no significant changes in the 30-day mortality attributable to bacteremia during the study period (P = 0.57 for trend)., Conclusion: The comprehensive ASPs had long-term efficacy for reducing the use of the targeted broad-spectrum antibiotics, maintaining the antibiotic susceptibility of P. aeruginosa, and decreasing the prevalence of MRSA, without adversely affecting clinical outcome.
- Published
- 2018
- Full Text
- View/download PDF
133. Improved bacterial identification directly from urine samples with matrix-assisted laser desorption/ionization time-of-flight mass spectrometry.
- Author
-
Kitagawa K, Shigemura K, Onuma KI, Nishida M, Fujiwara M, Kobayashi S, Yamasaki M, Nakamura T, Yamamichi F, Shirakawa T, Tokimatsu I, and Fujisawa M
- Subjects
- Bacteria classification, Bacteria isolation & purification, Bacterial Load, Humans, Urine microbiology, Bacteria chemistry, Molecular Typing methods, Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization methods, Urinary Tract Infections diagnosis, Urinary Tract Infections microbiology
- Abstract
Background: Matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI-TOF MS) contributes to rapid identification of pathogens in the clinic but has not yet performed especially well for Gram-positive cocci (GPC) causing complicated urinary tract infection (UTI). The goal of this study was to investigate the possible clinical use of MALDI-TOF MS as a rapid method for bacterial identification directly from urine in complicated UTI., Methods: MALDI-TOF MS was applied to urine samples gathered from 142 suspected complicated UTI patients in 2015-2017. We modified the standard procedure (Method 1) for sample preparation by adding an initial 10 minutes of ultrasonication followed by centrifugation at 500 g for 1 minutes to remove debris such as epithelial cells and leukocytes from the urine (Method 2)., Results: In 133 urine culture-positive bacteria, the rate of corresponded with urine culture in GPC by MALDI-TOF MS in urine with standard sample preparation (Method 1) was 16.7%, but the modified sample preparation (Method 2) significantly improved that rate to 52.2% (P=.045). Method 2 also improved the identification accuracy for Gram-negative rods (GNR) from 77.1% to 94.2% (P=.022). The modified Method 2 significantly improved the average MALDI score from 1.408±0.153 to 2.166±0.045 (P=.000) for GPC and slightly improved the score from 2.107±0.061 to 2.164±0.037 for GNR., Conclusion: The modified sample preparation for MALDI-TOF MS can improve identification accuracy for complicated UTI causative bacteria. This simple modification offers a rapid and accurate routine diagnosis for UTI, and may possibly be a substitute for urine cultures., (© 2017 Wiley Periodicals, Inc.)
- Published
- 2018
- Full Text
- View/download PDF
134. Comparison of antibiotics use, urinary tract infection (UTI)-causative bacteria and their antibiotic susceptibilities among 4 hospitals with different backgrounds and regions in Japan.
- Author
-
Shigemura K, Kitagawa K, Osawa K, Yamamichi F, Tokimatsu I, Nomi M, Takaba K, and Fujisawa M
- Subjects
- Bacterial Infections drug therapy, Drug Resistance, Bacterial, Humans, Japan, Microbial Sensitivity Tests, Anti-Bacterial Agents therapeutic use, Drug Resistance, Microbial, Urinary Tract Infections drug therapy, Urinary Tract Infections microbiology
- Abstract
In this study, we compared the antibiotic use, urinary tract infection-causative bacteria and their antibiotic susceptibilities among four hospitals with different backgrounds and regions in Japan in 2014. Frequency of antibiotic use (antibiotic use density: AUD/all AUD) were: ampicillin: 0.21-20.3 (median: 1.6) and cefazolin: 0.8-34.2 (2.5), representatively. The antibiotic resistant rates of Escherichia coli were ampicillin: 1.1-52.3% (median: 51.8%), piperacillin: 47.9-49.1% (48.0%), cefazolin: 23.2-34.1% (28.9%), levofloxacin: 36.6-43.8% (40.2%).We found that there were significant correlations (1) between antibiotic resistance of E. coli and annual total amount of antibiotic use (p = 0.017), annual number of days of antibiotic use (p = 0.002) and days of therapy (DOT, p = 0.002), and (2) between antibiotic resistance of extended-spectrum β-lactamase-producing bacteria and annual number of days of antibiotic use (p = 0.004) and DOT (p = 0.004) in a rehabilitation hospital. These results suggested that more antibiotic uses could lead to antibiotic resistances. Further analyses with more number of data are being undertaken.
- Published
- 2018
- Full Text
- View/download PDF
135. A New Amino Acid Substitution at G150S in Lanosterol 14-α Demethylase (Erg11 protein) in Multi-azole-resistant Trichosporon asahii.
- Author
-
Kushima H, Tokimatsu I, Ishii H, Kawano R, Watanabe K, and Kadota JI
- Subjects
- DNA, Fungal genetics, Fluconazole pharmacology, Point Mutation, Sequence Analysis, DNA, Trichosporon genetics, Amino Acid Substitution genetics, Antifungal Agents pharmacology, Azoles pharmacology, Drug Resistance, Fungal genetics, Genes, Fungal genetics, Sterol 14-Demethylase chemistry, Sterol 14-Demethylase genetics, Trichosporon drug effects, Trichosporon enzymology
- Abstract
The mechanisms of azole resistance in Trichosporon asahii have not yet been fully clarified. We previously showed that T. asahii has the ERG11 gene, coding lanosterol 14-α-demethylase (Erg11 protein; Erg11p), which is the primary target of azoles. A single amino acid substitution at G453R in Erg11p was found to induce changes in the affinity of this enzyme for azoles, especially fluconazole, in vitro. In the present study, we investigated the DNA sequences of the ERG11 gene using six different strains of clinically isolated T. asahii that were highly resistant to multi-azoles, including fluconazole, itraconazole, and voriconazole. All of the T. asahii strains had a point mutation (G448A) that caused a single amino acid substitution at G150S in Erg11p. This amino acid is highly conserved among major fungal pathogens. We identified a new point mutation in the ERG11 gene that is common to clinically isolated azole-resistant T. asahii strains, suggesting that this mutation is associated with the multi-azole resistance of T. asahii.
- Published
- 2017
- Full Text
- View/download PDF
136. Fungemia due to Trichosporon dermatis in a patient with refractory Burkitt's leukemia.
- Author
-
Hashino S, Takahashi S, Morita R, Kanamori H, Onozawa M, Kawamura T, Kahata K, Kondo T, Tokimatsu I, Sugita T, Akizawa K, and Asaka M
- Published
- 2013
- Full Text
- View/download PDF
137. [Current anti-influenza virus chemotherapy].
- Author
-
Yoshioka D, Tokimatsu I, Ishii H, and Kadota J
- Subjects
- Acids, Carbocyclic, Amantadine pharmacology, Antiviral Agents pharmacology, Cyclopentanes administration & dosage, Cyclopentanes pharmacology, Drug Resistance, Viral, Drug Utilization standards, Guanidines administration & dosage, Guanidines pharmacology, Humans, Influenza, Human epidemiology, Influenza, Human virology, Infusions, Intravenous, Japan, Oseltamivir pharmacology, Pandemics, Zanamivir pharmacology, Amantadine therapeutic use, Antiviral Agents therapeutic use, Cyclopentanes therapeutic use, Guanidines therapeutic use, Influenza A Virus, H1N1 Subtype drug effects, Influenza, Human drug therapy, Oseltamivir therapeutic use, Zanamivir therapeutic use
- Abstract
The environment surrounding influenza is changing in recent years. In the spring of 2009, pandemic (H1N1) 2009 occurred in Mexico, and became epidemic on a global scale thereafter. Therefore, control of influenza is very important all over the world. Now in Japan, four specific anti-influenza antiviral drugs are available: amantadine, oseltamivir, zanamivir and peramivir. Pandemic (H1N1) 2009 are amantadine-resistant viruses, thus is not recommended for use. Oseltamivir is most commonly used in Japan, however, we have to pay attention to oseltamivir-resistant influenza virus. Almost no zanamivir-resistant influenza virus has been so far reported. In Japan, peramivir is the first drip infusion medicine and is expected to be used in severe cases.
- Published
- 2010
138. [Allergic bronchopulmonary mycosis induced by Schizophyllum commune--case report and review of the literature].
- Author
-
Amemiya Y, Shirai R, Tokimatsu I, Oka H, Iwata A, Otani S, Umeki K, Sakashita H, Ishii H, Gendo Y, Kishi K, Hiramatsu K, and Kadota J
- Subjects
- Humans, Male, Middle Aged, Lung Diseases, Fungal etiology, Schizophyllum immunology
- Abstract
A 55-year-old man was admitted to our hospital because of pyrexia, cough and sputum. He suffered from bronchial asthma. Chest X-ray showed infiltrates in the left upper and right lower lung fields. Chest CT scans showed mucoid impaction and consolidation predominantly in the left upper lobe. Laboratory tests showed peripheral eosinophilia, elevated level of serum IgE, and the increased eosinophils in his sputum. Schizophyllum commune was isolated from the bronchoscopically-removed mucous plug. A diagnosis of allergic bronchopulmonary mycosis (ABPM) due to S. commune was made. Simultaneous daily administration of 400 mg itraconazole (ITCZ) and corticosteroid (prednisolone; 30 mg daily) provided sufficient improvement. However recurrence was recognized on chest CT scan findings one year later. There are not enough case reports concerning S. commune-induced ABPM to establish a therapeutic approach to the condition.
- Published
- 2009
139. [Sarcoidosis with epididymal and testicular lesions: case report and a review of the literature].
- Author
-
Iwasaki T, Ishii H, Otani S, Oka H, Amemiya Y, Iwata A, Umeki K, Shirai R, Kishi K, Tokimatsu I, Hiramatsu K, and Kadota J
- Subjects
- Adolescent, Humans, Male, Sarcoidosis diagnosis, Epididymis pathology, Sarcoidosis pathology, Testis pathology
- Abstract
A 47-year-old man was admitted for further examination of uveitis. He had noticed scrotal swelling before his admission. A computed tomographic scan of the chest showed hilar and mediastinal lymphadenopathy, multiple micronodules and thickening of the interlobular septum, and these findings were consistent with sarcoidosis. Bronchoalveolar lavage fluid showed lymphocytosis. Gallium-67 scintigraphy revealed an abnormal accumulation in the hilar and mediastinal lymph nodes and in the bilateral scrotum. The resected and biopsied specimens of the epididymis and testis demonstrated numerous noncaseating epithelioid cell granulomas but no evidence of neoplasm. Therefore, systemic sarcoidosis was diagnosed. A review of the Japanese literature found most cases to be associated with a history of painless scrotal swelling with chest roentgenogram findings of stage I or II, while also indicating it was important to perform biopsy or surgically resect any epididymal and testicular lesion.
- Published
- 2009
140. [Acute eosinophilic pneumonia caused by several drugs including ibuprofen].
- Author
-
Anan E, Shirai R, Kai N, Ishii H, Hirata N, Kishi K, Tokimatsu I, Nakama K, Hiramatsu K, and Kadota J
- Subjects
- Acetaminophen adverse effects, Acetaminophen immunology, Acute Disease, Adult, Analgesics, Non-Narcotic immunology, Cephalosporins adverse effects, Cephalosporins immunology, Humans, Ibuprofen immunology, Lymphocyte Activation, Male, Methylprednisolone administration & dosage, Prednisolone administration & dosage, Pulmonary Eosinophilia drug therapy, Tablets, Treatment Outcome, Analgesics, Non-Narcotic adverse effects, Ibuprofen adverse effects, Pulmonary Eosinophilia chemically induced
- Abstract
A 41-year-old woman took an EVE-A tablet, which contained ibuprofen, because of pyrexia over 39 degrees C. Due to continued pyrexia, she visited a physician and received cefcapene and acetaminophen under a diagnosis of cold. However, next day, she was admitted to our hospital with severe hypoxemia and pulmonary infiltrates on chest radiograph. Analysis of bronchoalveolar lavage fluid disclosed an increased proportion of 66% eosinophils. All of the lymphocyte stimulation tests for EVE-A tablet, cefcapene and acetaminophen showed positive. After the cessation of these drugs, she was successfully treated with steroids. This case was diagnosed as eosinophilic pneumonia caused by several drugs, and to our knowledge, this is the first report in Japan of ibuprofen (EVE-A tablet)-induced pneumonia.
- Published
- 2009
141. [A case of eosinophilic pneumonia due to Nicolase (serrapeptase) after recovery from acute eosinophilic pneumonia].
- Author
-
Kai N, Shirai R, Hirata N, Iwata A, Umeki K, Ishii H, Kishi K, Tokimatsu I, Hiramatsu K, and Kadota J
- Subjects
- Acute Disease, Adult, Female, Humans, Pharyngitis drug therapy, Recurrence, Anti-Inflammatory Agents, Non-Steroidal adverse effects, Peptide Hydrolases adverse effects, Pulmonary Eosinophilia chemically induced
- Abstract
A case of eosinophilic pneumonia due to Nicolase (serrapeptase) after recovery from acute eosinophilic pneumonia is described. A 32-year-old woman was previously admitted to another hospital because of acute onset of dyspnea accompanied by cough and fever. Chest X-ray films revealed diffuse infiltration in both lungs two days after her symptoms occurred. Her bronchoalveolar lavage fluid showed 13% eosinophils and transbronchial lung biopsy specimen also showed many eosinophils infiltrating in the lesions of the bronchial submucosa and alveolar septa. No infectious causes or related drugs were found. Acute eosinophilic pneumonia was diagnosed, and her condition improved gradually without steroid treatment. Because she recovered clinically and radiologically, she was discharged from hospital. Half a month later she was treated with Nicolase because of pharyngitis. She was admitted to the hospital again because of dyspnea, cough and fever three days after commencing to take Nicolase. Chest X-ray films also revealed diffuse infiltration in both lungs with pleural effusion, and her bronchoalveolar lavage fluid showed 37% eosinophils. When the drug lymphocyte stimulation test was performed, it was positive for Nicolase. Therefore drug-induced eosinophilic pneumonia was diagnosed. This is a very rare case of Nicolase (serrapeptase)-induced eosinophilic pneumonia after recovering from acute eosinophilic pneumonia.
- Published
- 2009
142. [Trichosporonosis].
- Author
-
Tokimatsu I
- Subjects
- Animals, Antifungal Agents administration & dosage, Humans, Immunocompromised Host, Neutropenia, Risk Factors, Diabetes Complications, Mycoses diagnosis, Mycoses drug therapy, Mycoses epidemiology, Mycoses microbiology, Trichosporon isolation & purification
- Abstract
Trichosporonosis is rare but have been associated with a wide spectrum of clinical manifestation, ranging from superficial infection to severe deep-seated mycosis. Deep-seated trichosporonosis is a lethal opportunistic infection occasionally found in immunocompromised patients, particularly those who are neutropenic due to hematological diseases or cytotoxic therapy. Trichosporon asahii is considered the principal etiologic agent of non-Candida fungemia and disseminated trichosporonosis in Japan. It is necessary for a clinician to pay enough care as the lethal infections in immunocompromised host. Diabetic patients are also predisposed of trichosporonosis because of the impaired leukocyte function. I review the literature about trichosporonosis with the patients of diabetes mellitus.
- Published
- 2008
143. [A case of amyopathic dermatomyositis-associated interstitial pneumonia accompanied with massive hemothorax].
- Author
-
Umeki K, Ishii H, Yoshikawa H, Morinaga R, Kishi K, Shirai R, Tokimatsu I, Hiramatsu K, and Kadota J
- Subjects
- Humans, Male, Middle Aged, Dermatomyositis complications, Hemothorax complications, Lung Diseases, Interstitial etiology
- Abstract
A 53-year-old man was admitted to our department because of interstitial pneumonia found on chest computed tomography when he was given a diagnosis of amyopathic dermatomyositis. Bronchoalveolar lavage (BAL) fluid showed an increased total cell count and lymphocytosis. An acute exacerbation of interstitial pneumonia occurred just after the BAL. Although the administration of corticosteroid and immunosuppressant for the progressive interstitial pneumonia produced temporary improvement, left hemothorax suddenly occurred soon after initiating treatment. The hemothorax was improved by thoracic drainage alone, but the patient died due to progressive worsening of interstitial pneumonia. In this case, we could not clarify the etiological mechanism of the hemothorax, however, there was a possible link with amyopathic dermatomyositis-associated interstitial pneumonia.
- Published
- 2008
144. [Case of toxocariasis showing migratory nodular shadows with halos].
- Author
-
Hisamatsu Y, Ishii H, Kai N, Amemiya Y, Otani S, Morinaga R, Shirai R, Umeki K, Kishi K, Tokimatsu I, Hiramatsu K, and Kadota J
- Subjects
- Adult, Albendazole therapeutic use, Animals, Animals, Domestic parasitology, Anthelmintics therapeutic use, Cattle, Diagnosis, Differential, Dogs, Humans, Larva Migrans, Visceral drug therapy, Male, Meat parasitology, Serologic Tests, Toxocara canis, Treatment Outcome, Larva Migrans, Visceral diagnosis, Larva Migrans, Visceral parasitology, Lung diagnostic imaging, Tomography, X-Ray Computed
- Abstract
A 30-year-old man, who had kept a dog for nine years and often ate raw beef liver, visited a hospital because of a chest nodular shadow in the left lung field found on a checkup examination. Chest computed tomography obtained 8 days after the checkup showed no abnormal shadow in the left lung but two nodular shadows with halos in the right upper and lower lobes. Peripheral blood eosinophil counts and serum IgE values were elevated. Immunological examination including microplate ELISA showed a high titer of specific antibody against Toxocara canis in the serum. He was successfully treated with albentazole. Parasitic disease, especially toxocariasis, is an important consideration in the differential diagnosis of migratory nodular shadow with a halo on chest computed tomography, and serology is useful in diagnosis screening.
- Published
- 2008
145. [Chronic hypersensitivity pneumonitis induced by Shiitake mushroom cultivation: case report and review of literature].
- Author
-
Kai N, Ishii H, Iwata A, Umeki K, Shirai R, Morinaga R, Kishi K, Tokimatsu I, Hiramatsu K, Yamagata E, and Kadota J
- Subjects
- Aged, Alveolitis, Extrinsic Allergic therapy, Biomarkers analysis, Chronic Disease, Humans, Lymphocyte Activation, Male, Occupational Diseases therapy, Prednisolone administration & dosage, Tomography, X-Ray Computed, Alveolitis, Extrinsic Allergic diagnosis, Alveolitis, Extrinsic Allergic etiology, Occupational Diseases diagnosis, Occupational Diseases etiology, Occupational Exposure adverse effects, Shiitake Mushrooms immunology
- Abstract
A 72-year-old man, a Shiitake mushroom grower over fifty years, was admitted to our hospital because of bilateral chest interstitial shadow with chronic cough and breathlessness. Chest computed tomography showed traction bronchiectasis, subpleural micro-cystic changes and partial ground-glass opacities in both lungs, and mild mediastinal lymphadenopathy. A diagnosis of chronic hypersensitivity pneumonitis induced by Shiitake mushrooms was comprehensively confirmed by occupational history, radiological findings, and positive findings of an incidental environmental provocation test and lymphocyte stimulation test for Shiitake mushroom extracts. We reviewed the clinical features in five patients with chronic hypersensitivity pneumonitis induced by Shiitake mushrooms reported in Japan. There was a tendency toward increasing lymphocytes and high CD4/CD8 ratio in bronchoalveolar lavage fluids. Treatment with steroids seems to have a limited effect, while avoidance of the antigen is important.
- Published
- 2008
146. [Pulmonary metastasis of fibrosarcomatous variant of dermatofibrosarcoma protuberans: case report and review of literature].
- Author
-
Otani S, Ishii H, Hashinaga K, Morinaga R, Umeki K, Kishi K, Shirai R, Tokimatsu I, Hiramatsu K, Kawahar K, and Kadota J
- Subjects
- Humans, Male, Middle Aged, Dermatofibrosarcoma pathology, Lung Neoplasms secondary, Skin Neoplasms pathology
- Abstract
A 63-year-old man had undergone excision of a growing mass with a wide margin in the left supraclavicular fossa. A diagnosis of fibrosarcomatous variant of dermatofibrosarcoma protuberans (DFSP-FS) was made. Three years later, an abnormal chest shadow was detected on a medical checkup. Chest computed tomography showed a heterogeneously-enhanced 2-cm coin lesion with a distinct border in the right lower lobe and a 3-mm nodule in the left lower lobe. Transbronchial lung biopsy specimens from the right lung revealed a DFSP pattern. We then performed right basal segmentectomy and partial resection of the left lower lobe. DFSP is a relatively rare skin tumor that is considered to be intermediate malignancy. It frequently recurs locally but rarely has systemic metastasis. However, DFSP-FS, a subtype of DFSP, has an increased likelihood of systemic metastasis. The lung is the most common site of metastasis of DFSP-FS. DFSP-FS sometimes recurs even a long time after excision. Therefore, long-term follow-up, including chest X-ray and CT are important in DFSP-FS patients.
- Published
- 2008
147. [A case of Sweet's syndrome with a variety of chest radiological findings].
- Author
-
Kushima H, Mizunoe S, Ishii H, Hashinaga K, Yamasaki T, Kishi K, Tokimatsu I, Hiramatsu K, and Kadota J
- Subjects
- Adrenal Cortex Hormones therapeutic use, Aged, Anti-Inflammatory Agents administration & dosage, Humans, Male, Prednisolone administration & dosage, Sweet Syndrome drug therapy, Tomography, X-Ray Computed, Lung diagnostic imaging, Sweet Syndrome complications
- Abstract
We report a rare case of Sweet's syndrome (acute febrile neutrophilic dermatosis) with a variety of chest radiological findings. A 73-year-old man, who had been treated with corticosteroid for Sweet's syndrome for 2 years, was admitted to our hospital because of pyrexia with a infiltrative chest shadow. Chest CT scans showed consolidation and ground-glass opacities with air-bronchogram in the right lower lobe. Treatment with antibiotics seemed to be effective but there was no improvement of chest shadows. Simultaneously with his pyrexia, diffuse centrilobular-micronodular shadows and a mass-like shadow appeared on chest CT after 2 months and after the next 2 months, respectively. Bronchoalveolar lavage fluid contained increased neutrophils but not any infectious pathogen. Transbronchial lung biopsy specimens revealed chronic interstitial infiltrate with alveolar wall thickening and neutrophil accumulation in the airspace. A diagnosis of pulmonary involvement in a patient with Sweet's syndrome was finally made and he was successfully treated with corticosteroid.
- Published
- 2007
148. [Pulmonary lymphomatoid granulomatosis radiologically mimicking interstitial pneumonia].
- Author
-
Ishii H, Kishi K, Kushima H, Hashinaga K, Umeki K, Ohama M, Tokimatsu I, Hiramatsu K, and Kadota J
- Subjects
- Diagnosis, Differential, Herpesvirus 4, Human, Humans, Lung Diseases pathology, Lung Diseases, Interstitial, Lymphomatoid Granulomatosis pathology, Male, Middle Aged, Radiography, Thoracic, Tomography, X-Ray Computed, Lung Diseases diagnostic imaging, Lymphomatoid Granulomatosis diagnostic imaging
- Abstract
We report a rare case of pulmonary lymphomatoid granulomatosis radiologically mimicking interstitial pneumonia. A 57-year-old man was admitted to our hospital because of chest bilateral reticular shadow with sustained cough and breathlessness for 10 years. Chest CT scans showed multiple ground-glass opacities, traction bronchiectasis and cystic change in both lungs, in addition to hilar and mediastinal lymphadenopathy. A histopathologically diagnosis of pulmonary lymphomatoid granulomatosis (angiocentric immunoproliferative lesion, grade 1) was made by thoracoscopic lung biopsy. In this case, serological and immunohistochemical analyses did not show Epstein-Barr virus infection. No clinical or radiological deterioration has been observed thereafter despite no medication.
- Published
- 2007
149. [A case of diaphragmatic paralysis caused by herpes zoster after anticancer chemotherapy].
- Author
-
Morinaga R, Matsunaga N, Iwata A, Kishi K, Tokimatsu I, Nagai H, and Kadota J
- Subjects
- Antineoplastic Combined Chemotherapy Protocols therapeutic use, Carcinoma, Adenosquamous drug therapy, Carcinoma, Adenosquamous surgery, Cisplatin administration & dosage, Drug Administration Schedule, Female, Humans, Lung Neoplasms drug therapy, Lung Neoplasms surgery, Lymph Node Excision, Middle Aged, Pneumonectomy, Vinblastine administration & dosage, Vinblastine analogs & derivatives, Vinorelbine, Antineoplastic Combined Chemotherapy Protocols adverse effects, Herpes Zoster chemically induced, Herpes Zoster complications, Respiratory Paralysis etiology
- Abstract
A 61-year-old woman who had been followed up after resection of lung cancer (adenosquamous cell carcinoma), was admitted to our hospital because of recurrence. She received systemic anticancer chemotherapy and the chief adverse event was leukopenia (Grade 3). Nineteen days after initiating chemotherapy, she suffered painful vesicular eruption on the right upper limb and the right upper hemithorax which was diagnosed as herpes zoster. After treatment with anti-viral drugs the vesicular eruption disappeared, but chest X-ray film revealed a right diaphragmatic relaxation. Although herpes zoster virus usually affects sensory nerves and causes painful vesicular eruption, it can also damage motor nerves. Herpes zoster virus almost affects cranial nerves, but it should be considered as the cause of diaphragmatic paralysis in this case.
- Published
- 2007
150. [A case of bronchiolitis possibly associated with inhalation of hard metal].
- Author
-
Ishii H, Umeki K, Yoshikawa H, Kushima H, Hashinaga K, Ohama M, Kishi K, Tokimatsu I, Hiramatsu K, and Kadota J
- Subjects
- Adult, Bronchiolitis diagnosis, Bronchoalveolar Lavage Fluid cytology, Humans, Inhalation, Male, Radiography, Thoracic, Tungsten Compounds adverse effects, Bronchiolitis chemically induced, Environmental Exposure adverse effects, Metallurgy, Metals adverse effects
- Abstract
A 36-year-old man, a worker exposed to tungsten and cobalt compounds, was admitted because of chest bilateral micronodular shadow with chronic cough and sputum. Chronic sinusitis, mild hypoxemia, obstructive respiratory impairment and chest radiological findings fulfilled the Japanese diagnostic criteria for diffuse panbronchiolitis, while atypical bronchoalveolar lavage fluid and pathological findings were seen. The surgical lung biopsy specimens showed patchy centrilobular inflammatory change with monocytic infiltrations and particulate deposition inside the area of bronchiolitis, but neither tungsten nor cobalt was found. Treatment with a macrolide antibiotic had no effect on the patient's symptoms, hypoxemia and lung function, suggesting bronchiolitis associated with inhalation of hard metal.
- Published
- 2007
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.